Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III Adaptive Multicenter Clinical Study of XB20-01 for colorectal cancer

Next Previous
X
Search
Trial Profile

Phase II/III Adaptive Multicenter Clinical Study of XB20-01 for colorectal cancer

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 06 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilamakitug (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 May 2021 New trial record
    • 03 May 2021 According to XBiotech media release, French National Cancer Institute and XBiotech Join forces to conduct this trial
    • 03 May 2021 According to XBiotech media release, Dr. Francois Ghiringhelli M.D. Ph.D, is lead investigator of this trial who designed the study which features an innovative interim analysis to assess improvement in overall survival. If patients receiving XB20-01 have a predetermined improvement in survival compared to the placebo treated group, the randomized study will be expanded to enroll a phase III portion with overall survival as the primary outcome.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top